Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Hemodialysis Clearance"'
Autor:
Katheryne Z. Edson, Benjamin M. Wu, Abhinaya Iyer, William Goodman, Gary L. Skiles, Raju Subramanian
Publikováno v:
Kidney International Reports, Vol 1, Iss 1, Pp 24-33 (2016)
Etelcalcetide, a novel calcimimetic agonist of the calcium-sensing receptor for treatment of secondary hyperparathyroidism in chronic kidney disease patients on hemodialysis, is a d-amino acid linear heptapeptide with a d-cysteine that is linked to a
Externí odkaz:
https://doaj.org/article/ddf2ccf57a3d440691c4a49cddbc1f17
Autor:
Hiroyuki Yamada, Sudhakar M. Pai
Publikováno v:
Clinical Pharmacology in Drug Development. 10:463-470
The dialysis clearance of enarodustat (JTZ-951) was determined in patients (N = 6) with end-stage renal disease on hemodialysis. Enarodustat (5 mg PO) was administered before (day 1) and after hemodialysis (day 8) with pharmacokinetic assessments on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cb0cb98c182f1b02c80b307a6912ef6
https://doi.org/10.1002/cpdd.923
https://doi.org/10.1002/cpdd.923
Publikováno v:
Advances in Therapy
Amenamevir (ASP2151), a herpesvirus helicase-primase inhibitor, is currently used for the treatment of herpes zoster in Japan. Amenamevir is mainly metabolized in the liver, and urinary excretion of amenamevir is approximately 10% in healthy adults.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::887feb91a7c4d58998b3eeab1fd81fb3
https://doi.org/10.1007/s12325-020-01489-6
https://doi.org/10.1007/s12325-020-01489-6
Publikováno v:
Advances in Therapy
Introduction Amenamevir (ASP2151), a herpesvirus helicase-primase inhibitor, is currently used for the treatment of herpes zoster in Japan. Amenamevir is mainly metabolized in the liver, and urinary excretion of amenamevir is approximately 10% in hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24ceb9e437a45379323a3922c375581b
http://europepmc.org/articles/PMC7547951
http://europepmc.org/articles/PMC7547951
Publikováno v:
J Med Toxicol
OBJECTIVE: Although hemodialysis is recommended for patients with severe metformin-associated lactic acidosis (MALA), the amount of metformin removed by hemodialysis is poorly documented. We analyzed endogenous clearance and hemodialysis clearance in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d44709a57b505d420a22d5b421d3881
https://europepmc.org/articles/PMC7785761/
https://europepmc.org/articles/PMC7785761/
Publikováno v:
Artificial Organs. 43:261-269
The aim of this study was to analyze the differences between vancomycin clearance (Kd) with high-flux hemodialysis (HFHD) and on-line hemodiafiltration (OL-HDF). The OL-HDF therapy combined the diffusion and convective transport of solutes. To compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09207911d0311e4d42957f7190a11309
https://doi.org/10.1111/aor.13368
https://doi.org/10.1111/aor.13368
Autor:
Gary L. Skiles, Abhinaya Iyer, Katheryne Z. Edson, Benjamin M. Wu, William G. Goodman, Raju Subramanian
Publikováno v:
Kidney International Reports, Vol 1, Iss 1, Pp 24-33 (2016)
Kidney International Reports
Kidney International Reports
Introduction Etelcalcetide, a novel calcimimetic agonist of the calcium-sensing receptor for treatment of secondary hyperparathyroidism in chronic kidney disease patients on hemodialysis, is a d -amino acid linear heptapeptide with a d -cysteine that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06eccb0620f063fe3d02fe8de7463f67
http://www.sciencedirect.com/science/article/pii/S2468024916300031
http://www.sciencedirect.com/science/article/pii/S2468024916300031
Autor:
Akiyoshi Kikkawa, Junki Nakajima, Takahiko Aoyama, Aoi Miyamoto, Yoshiaki Matsumoto, Daisuke Suzuki, Kouichi Hiraki, Yumina Ako
Publikováno v:
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis TherapyREFERENCES. 24(6)
Hemodialysis (HD) is a method used to remove biogenic substances or blood components that cause disease and some drugs used by patients to treat their diseases. Therefore, dosing schedule must be planned according to HD clearance (CLHD ) when medical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ebf77a02f7a128923d5ac65e967b9af
https://pubmed.ncbi.nlm.nih.gov/31916669
https://pubmed.ncbi.nlm.nih.gov/31916669
Publikováno v:
Journal of Clinical Pharmacology
Serelaxin, a recombinant human relaxin‐2 hormone, is in clinical development for treating acute heart failure. This open‐label, parallel‐group study investigated serelaxin pharmacokinetics (PK) after a single 4‐hour intravenous infusion (10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78db0f0187936f2474bd85b28e07d4d0
https://doi.org/10.1002/jcph.607
https://doi.org/10.1002/jcph.607